CN112691115A - Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury - Google Patents
Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury Download PDFInfo
- Publication number
- CN112691115A CN112691115A CN202110135233.2A CN202110135233A CN112691115A CN 112691115 A CN112691115 A CN 112691115A CN 202110135233 A CN202110135233 A CN 202110135233A CN 112691115 A CN112691115 A CN 112691115A
- Authority
- CN
- China
- Prior art keywords
- arabinoxylan
- solution
- food
- use according
- konjac flour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000617 arabinoxylan Polymers 0.000 title claims abstract description 132
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 title claims abstract description 129
- 230000002496 gastric effect Effects 0.000 title claims abstract description 30
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 29
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 24
- 235000013312 flour Nutrition 0.000 claims abstract description 23
- 229920002752 Konjac Polymers 0.000 claims abstract description 22
- 239000000252 konjac Substances 0.000 claims abstract description 20
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 19
- 235000010485 konjac Nutrition 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 15
- 239000003513 alkali Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 5
- 239000012535 impurity Substances 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 11
- 229920002581 Glucomannan Polymers 0.000 claims description 11
- 229940046240 glucomannan Drugs 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000000909 electrodialysis Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000021581 juice product Nutrition 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- 239000010902 straw Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002386 leaching Methods 0.000 abstract description 2
- 241001312219 Amorphophallus konjac Species 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
- 230000006378 damage Effects 0.000 description 35
- 241000700159 Rattus Species 0.000 description 27
- 210000001156 gastric mucosa Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 208000014674 injury Diseases 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000004062 sedimentation Methods 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000035622 drinking Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004357 Transferases Human genes 0.000 description 4
- 108090000992 Transferases Proteins 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- HMFHBZSHGGEWLO-QMKXCQHVSA-N alpha-L-arabinofuranose Chemical compound OC[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-QMKXCQHVSA-N 0.000 description 3
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- 150000004783 arabinoxylans Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- -1 small-molecule organic acids Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000909131 Homo sapiens Cytochrome P450 2E1 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003616 gastrointestinal mucosa protective agent Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of arabinoxylan or a compound of the arabinoxylan and konjac flour in preparing food, health-care products or medicines for preventing/treating alcoholic gastrointestinal mucosa and liver injury. The arabinoxylan is prepared by pretreating plant raw materials to remove impurities, and then leaching with alkali liquor, dealkalizing and purifying. In the compound of the arabinoxylan and the konjac flour, the mass percentage of the arabinoxylan is 1-99%. The food, the health care product or the medicine for preventing/treating the alcoholic gastrointestinal mucosa and liver injury, which is prepared from the arabinoxylan alone or the compound of the arabinoxylan and the konjac flour, can effectively reduce the alcoholic gastrointestinal mucosa and liver injury.
Description
Technical Field
The invention belongs to the technical field of medicines and foods, and particularly relates to arabinoxylan and a compound for preventing/treating gastrointestinal mucosa and liver injury.
Background
Drinking is a traditional preference for people and gradually has social interaction properties, but excessive drinking can not only cause liver damage, but also damage to blood, digestion, cardiovascular and central nervous systems to different degrees. Alcohol is an organic solvent, readily penetrates biological membranes, can be absorbed through respiratory and digestive mucosa, and is absorbed in a small part by skin and other mucosa, and the speed and degree of absorption depend on the alcohol concentration gradient at the absorption site, the permeability of the membrane and the local blood flow.
The liver is the main organ of alcohol metabolism, more than 90% of alcohol ingested by the body is metabolized in the liver, and after entering the liver, the alcohol is oxidized into acetaldehyde through Alcohol Dehydrogenase (ADH), liver microsome alcohol oxidase system (MEOS) and catalase. Alcoholic liver injury (alcoholic liver injury) is a liver disease caused by long-term or heavy drinking, is manifested as fatty liver at the initial stage, and further can develop into alcoholic hepatitis, hepatic fibrosis and liver cirrhosis, and serious patients can induce liver cancer and liver function failure, and is listed as one of the main causes of death caused by liver diseases in western countries. The first step of the alcohol metabolism process (i.e., the step of metabolizing ethanol to acetaldehyde) is mainly achieved by two oxidation systems, one is an intracytoplasmic ethanol oxidation system through which approximately 80% of the ethanol ingested into the body is metabolized, and the other is a Microsomal Ethanol Oxidation System (MEOS) through which approximately 20% of the ethanol ingested into the body is metabolized. The enzyme participating in ethanol metabolism in MEOS is mainly cytochrome P4502E1 (cytochromeP 4502E1, CYP2E 1), and can generate obvious induction effect on the MEOS after long-term drinking. When the concentration of ethanol is lower, the ethanol is mainly decomposed by an intracytoplasmic ethanol oxidation system; if the ethanol concentration is too high, the metabolism must be carried out by means of MEOS at the same time. The high concentration of ethanol in vivo caused by long-term drinking can induce the massive expression of the key enzyme CYP2E1 in MEOS, and at the moment, the ethanol is mainly metabolized by the MEOS to generate a large amount of active oxygen free radicals, which is one of the important mechanisms of the ethanol for causing liver injury.
The gastrointestinal tract is also involved in alcohol metabolism, the gastrointestinal tract mucosa has certain metabolic capacity on alcohol, namely First Pass Metabolism (FPM), the normal gastrointestinal tract mucosa function is maintained, the action time of alcohol and gastrointestinal tract mucosa Alcohol Dehydrogenase (ADH) is prolonged, the first pass metabolic level is enhanced, and the blood alcohol concentration (SEC) is reduced. Alcohol enters the intestinal tract and is metabolized into acetaldehyde by microorganisms, the acetaldehyde can increase the permeability of gastrointestinal tract cells, the probability of leakage of enterogenic endotoxin to liver blood circulation is improved, secondary attack is formed, and liver injury is aggravated. In addition, the high permeability of small intestine to pathogenic factors such as endotoxin and bacteria can cause fever, leukocytosis, microcirculation disturbance, shock, multiple organ failure, etc. Thus, although alcohol is metabolized to a much lesser extent in the gastrointestinal tract than the liver, protection of the gastrointestinal mucosa remains of great significance in reducing alcoholic liver injury.
Arabinoxylan (AX) is an important functional hemicellulose in the cell walls of the outer layers and endosperm of cereals, and AX is mainly distributed in grain crops such as wheat, barley, oat, rice, sorghum and millet, and is also abundant in crops such as linseed and banana peel. The structure of AX is formed by connecting xylan with beta-D-xylopyranose residues through beta- (1 → 4) glycosidic bonds as a main chain and alpha-L-arabinofuranose as a side chain. The beta-D-xylose residue may be mono-substituted at the C2 and C3 positions with alpha-L-arabinofuranose, or may be di-substituted at the C2 and C3 positions with alpha-L-arabinofuranose. In addition, ferulic acid is present in ester linkage at position C5 of certain arabinosyl groups, which are normally linked at position C3 of the xylose residue, the presence of ferulic acid being important for the functional properties of AX. An important indicator of the structural characteristics of arabinoxylan is the average degree of substitution of its xylan backbone, i.e. the relative number of Ara/Xly (a/X) and arabinose residues and the differences in substitution; this is the main reason for differences in properties such as solubility, solution viscosity, gelling properties, and degree of enzymatic action of arabinoxylans. According to the difference of the solubility of arabinoxylan in water, the arabinoxylan is classified into water-soluble arabinoxylan (WSAX) and water-insoluble arabinoxylan (WISAX), and compared with WSAX, WISAX has larger molecular weight, high branching degree (lower ratio of arabinose to xylose) and higher ferulic acid content. AX improves dough properties and bread baking quality well and can be developed as a thickener, humectant, bread additive, etc. AX has a number of important physiological functions; as dietary fiber, has the effects of relaxing bowel, losing weight and beautifying; as an immunomodulator, the composition can activate Natural Killer (NK) cells, T and B lymphocytes and enhance the immune function of human body; in addition, AX also has various physiological functions of regulating blood sugar level, reducing blood lipid, resisting oxidation, promoting intestinal peristalsis, resisting tumor, improving immunity, etc. However, there is no report on the use of arabinoxylan for the prevention/treatment of alcoholic gastrointestinal mucosal and liver damage.
Water extraction, chemical extraction, enzyme extraction and mechanical auxiliary extraction are widely applied to AX production, and an alkali solvent method and a mechanical auxiliary method have higher extraction efficiency according to the extraction yield of AX, but are difficult to apply to industrial production due to the problems of cost, instrument safety, environment and the like; the yield of the enzyme method is lower, but the enzyme method can be combined with a mechanical auxiliary method and a chemical solvent method to improve the yield of AX; the mechanical auxiliary method has the function of improving the yield of AX, wherein the steam explosion method and the extrusion method both have the advantage of environmental friendliness and are suitable for industrial production. The existing research on AX also focuses on the aspects of process conditions such as yield and purity, intestinal microecology, physiological metabolism, body immune function intervention and the like, and the research on the protection function of AX or a compound thereof for preventing/treating alcoholic gastrointestinal mucosa and liver injury is not reported.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides arabinoxylan and a compound for preventing/treating gastrointestinal mucosa and liver injury, and specifically provides a food, a health product or a medicine prepared from the arabinoxylan alone or the compound of the arabinoxylan and konjac flour and used for preventing/treating alcoholic gastrointestinal mucosa and liver injury, which can effectively reduce the injury of alcohol to the gastrointestinal mucosa and the liver.
Application of arabinoxylan or its compound with rhizoma Amorphophalli powder in preparing food, health product or medicine for preventing/treating alcoholic gastrointestinal mucosa and liver injury is provided.
In the compound of the arabinoxylan and the konjac flour, the mass percentage of the arabinoxylan is 1-99%.
Preferably, the arabinoxylan has a glycan content of > 60%.
Preferably, the glucomannan content in the konjac flour is > 60%.
The arabinoxylan is prepared by pretreating plant raw materials, removing impurities, leaching with alkali liquor, and dealkalizing and purifying.
The plant material comprises one or more of straw, corncob, bran or wood with hemicellulose component mainly comprising arabinoxylan.
Preferably, the specific preparation method of the arabinoxylan is as follows:
(1) crushing the plant raw materials, adding 8-12 times of NaOH solution with weight and mass concentration of 0.2-1.0%, carrying out heat preservation treatment at 40-90 ℃ for 1.5-2.5 h, replacing and washing with clear water, and then filtering and dehydrating to obtain the clean fiber.
(2) Adding 6-10 times of NaOH solution with the weight and the mass concentration of 8-12% into the obtained clean fiber, performing heat preservation extraction at 55-65 ℃ for 5.5-6.5 h, settling, centrifuging, collecting primary supernatant, performing continuous countercurrent displacement on residues by using NaOH solution with the weight of 8-12 times and the mass concentration of 3-5%, settling, centrifuging, collecting secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain the arabinoxylan aqueous solution.
(3) And (3) dealkalizing the arabinoxylan alkali solution, adding acid to neutralize the solution until the pH value is 6.0-8.0, concentrating and dehydrating the solution, adding clear water to perform continuous replacement desalting treatment, and drying the solution to obtain the arabinoxylan alkali solution.
Preferably, the first sedimentation centrifugation in the step (2) is performed by using a horizontal spiral sedimentation centrifuge, and the second sedimentation centrifugation is performed by using a butterfly centrifuge with a higher separation factor.
The dealkalization mode in the step (3) can adopt any one or combination of an ultrafiltration membrane filtration mode and an electrodialysis membrane replacement mode. Preferably, the ultrafiltration membrane has a cut-off of less than or equal to 10 kDa.
The acid used in the step (3) is any one of hydrochloric acid, citric acid or acetic acid, and the mass concentration is 4-6%.
Concentrating and dehydrating in the step (3) by adopting an ultrafiltration membrane filtration mode; preferably, the ultrafiltration membrane has a cut-off of less than or equal to 10 kDa.
The arabinoxylan alone or the compound of the arabinoxylan and the konjac flour is selectively added with conventional auxiliary materials and prepared into any acceptable dosage forms such as granules, powder, tablets, capsules or suspensions according to the conventional process, and the products can be used as common food, health food or medicines.
The arabinoxylan can be added into any other processed food or food material, and can exert function via different food carriers. The different food carriers comprise rice, flour products, dairy products, vegetable protein products, dry and fresh fruit juice products and the like.
The invention has the beneficial effects that:
the content of polysaccharide in the arabinoxylan is more than 60 percent, and the content of glucomannan in the konjac flour is more than 60 percent, wherein the arabinoxylan can be commercial arabinoxylan, and can also be the arabinoxylan prepared by the preparation method. The arabinoxylan is a polysaccharide main chain formed by connecting beta-D-xylopyranose residues through beta- (1 → 4) glycosidic bonds, and is also connected with arabinose, glucuronic acid and other groups as branched chains; when the polysaccharide content in the arabinoxylan is more than 60%, the arabinoxylan contains a large amount of water-insoluble arabinoxylan, maintains the natural macromolecular characteristics of the arabinoxylan, can be uniformly dispersed in water, has increased viscosity with the reduction of pH value, is even in a gel state, is difficult to decompose and destroy by gastric acid, and has little influence on the environment in the stomach and the small intestine. The stable physicochemical property and excellent physiological function make the arabinoxylan have the potential of being developed into a novel gastrointestinal mucosa protective agent. Konjaku flour is extracted from konjaku, and mainly contains glycan, called glucomannan, with mannose and glucose as two sugar groups, which are polymerized into a main chain by beta- (1 → 4) glycosidic bond. Glucomannan has various characteristics of hydrophile, thickening, stability, emulsification, suspension, gel, film formation and the like, is similar to the arabinoxylan, has good stability in stomach and small intestine due to lack of corresponding degrading enzyme, can be spread on the surface of gastrointestinal mucosa to form a mucosa-like protective layer, and reduces the direct contact and stimulation of alcohol to the mucosa; therefore, the content of glucomannan in the konjac flour is limited to be more than 60%, so that the protective effect of the compound on gastrointestinal mucosa is favorably improved.
In the preparation method of the arabinoxylan, the raw materials are deeply purified and extracted by dilute alkali low-temperature pretreatment, the food safety is high, the obtained arabinoxylan is also a high-purity macromolecular polysaccharide, and simultaneously contains water-soluble arabinoxylan and water-insoluble arabinoxylan, the content of hydrolysable polysaccharide in the arabinoxylan is up to more than 80%, the natural macromolecular characteristics of the arabinoxylan are greatly maintained, and the protective effect on gastrointestinal mucosa is strong.
The arabinoxylan also has the function of slowing down the gastric emptying speed, is favorable for improving the first-pass metabolism level and reducing the blood alcohol concentration, and simultaneously has a plurality of physiological functions of dietary fibers. The invention prepares the arabinoxylan into food, health care products or medicines which can be used for preventing/treating alcoholic gastrointestinal mucosa and liver injury, and is suitable for preventing or treating gastrointestinal mucosa and liver injury caused by long-term drinking or taking. The compound of the araboxylan and the konjac flour has more obvious curative effect than that of the araboxylan used alone, and can reach the level close to or even better than the effect of the positive medicament of the Oimera.
After the arabinoxylan and the glucomannan are fermented by specific microorganisms in the intestinal tract, short-chain fatty acids such as acetic acid, propionic acid, butyric acid and the like are highly produced, and the short-chain fatty acids participate in the regulation and control of metabolism, nerves and immune systems through the small-molecule organic acids. Wherein, the butyric acid is an energy substance of the epithelial cells of the digestive tract, can repair the epithelial cells of the damaged digestive tract and effectively inhibit the generation and the development of inflammatory reaction of the digestive tract. The acetic acid level is negatively correlated with inflammatory indexes of liver, kidney and other organs, and propionic acid participates in regulation and control of liver lipid metabolism, and has the functions of improving the activity of antioxidant enzyme of epithelial tissues of gastrointestinal wall, preventing fatty liver and improving gastrointestinal mucosa system. The arabinoxylan can also proliferate various known intestinal probiotics, and the probiotics can effectively reduce the generation of enterogenic endotoxins such as ammonia, phenols, indoles and the like, and play roles in relaxing bowel and improving immunity. In addition, the arabinoxylan is a nutritional ingredient which is taken in a large amount along with the main grain of the grains for a long time since the culture civilization of human farming, has extremely low possibility of interfering most medicaments, and can be mixed with other gastric mucosa and liver protection medicaments to improve the effect.
Drawings
FIG. 1 is a representative diagram of the damage of the gastric mucosa of rats in a normal control group, a model control group and a positive control group;
FIG. 2 is a representative diagram of the gastric mucosal injury in rats in the group of low dosage arabinoxylan, high dosage arabinoxylan, arabinoxylan complex (I) and arabinoxylan complex (II);
FIG. 3 is a pathological section of rats with gastric mucosa injury in model control group, arabinoxylan high dose group, arabinoxylan complex (I) group and arabinoxylan complex (II) group.
Detailed Description
In order to describe the present invention in more detail, the present invention will be further described with reference to the following examples.
Example 1
The specific preparation method of the arabinoxylan comprises the following steps:
(1) selecting 10kg of dry mildew-free cereal bran, adding 100kg of NaOH solution with the mass concentration of 0.2%, carrying out heat preservation treatment at 40 ℃ for 2h, replacing and washing with clear water, and then filtering and dehydrating to obtain clean fibers.
(2) Adding 80kg of NaOH solution with the mass concentration of 8% into the obtained clean fiber, performing heat preservation extraction at 60 ℃ for 6h, performing sedimentation centrifugation on the extract by using a horizontal spiral sedimentation centrifuge to collect primary supernatant, performing continuous countercurrent replacement on the residue by using 100kg of NaOH solution with the mass concentration of 4%, performing sedimentation centrifugation on the replacement solution by using a butterfly centrifuge to collect secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain 165kg of the arabinoxylan aqueous alkali.
(3) Dealkalizing the arabinoxylan alkali solution by an ultrafiltration membrane, slowly adding hydrochloric acid with the mass concentration of 5% while stirring to neutralize the solution to a pH value of 6.0-8.0, concentrating and dehydrating by the ultrafiltration membrane, adding clear water to perform continuous replacement desalting treatment, and performing spray drying to obtain 1.1kg of the arabinoxylan. The cutoff molecular weight of the ultrafiltration membrane is less than or equal to 10 kDa. The content of hydrolyzable polysaccharide in the finally obtained arabinoxylan is 82%, and all pollutant indexes are within the national standard range of grain food.
Example 2
The specific preparation method of the arabinoxylan comprises the following steps:
(1) selecting 1kg of dried, mildew-free and crushed corncobs, adding 10kg of NaOH solution with the mass concentration of 1.0%, carrying out heat preservation treatment at 90 ℃ for 2h, replacing and washing with clear water, and then filtering and dehydrating to obtain clean fibers.
(2) Adding 8kg of NaOH solution with the mass concentration of 10% into the obtained clean fiber, performing heat preservation extraction at 60 ℃ for 6h, performing sedimentation centrifugation on the extract by using a horizontal spiral sedimentation centrifuge to collect primary supernatant, performing continuous countercurrent replacement on the residue by using 10kg of NaOH solution with the mass concentration of 4%, performing sedimentation centrifugation on the replacement solution by using a butterfly centrifuge to collect secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain 16kg of the arabinoxylan aqueous alkali.
(3) And (2) after the arabinoxylan alkali solution is subjected to displacement dealkalization treatment by an electrodialysis membrane, slowly adding citric acid with the mass concentration of 5% while stirring to neutralize the solution to the pH value of 6.0-8.0, performing concentration and dehydration by using an ultrafiltration membrane with the molecular weight cutoff of less than or equal to 10kDa, adding clear water to perform continuous displacement desalination treatment, and performing spray drying to obtain 0.17kg of arabinoxylan. The content of hydrolyzable polysaccharide in the finally obtained arabinoxylan is 88%, and all pollutant indexes are within the national standard range of grain food.
Example 3
Arabinoxylan complex (i) for preventing/treating gastrointestinal mucosal and liver injury was prepared by mixing 80 parts by weight of arabinoxylan of example 1 and 20 parts by weight of commercially available konjac flour having a glucomannan content of 85%.
Arabinoxylan complex for preventing/treating gastrointestinal mucosa and liver injury, which was obtained by mixing 95 parts by weight of arabinoxylan of example 1 and 5 parts by weight of commercially available konjac flour having a glucomannan content of 85%.
Arabinoxylan complex for preventing/treating gastrointestinal mucosa and liver injury, which is obtained by mixing 80 parts by weight of arabinoxylan of example 2 and 20 parts by weight of commercially available konjac flour having a glucomannan content of 85%.
Arabinoxylan complex (iv) for preventing/treating gastrointestinal mucosal and liver injury was obtained by mixing 95 parts by weight of arabinoxylan of example 2 and 5 parts by weight of commercially available konjac flour having a glucomannan content of 85%.
In order to verify the efficacy of the arabinoxylan or the complex of arabinoxylan and konjac flour of the present invention in preventing alcoholic gastrointestinal mucosa and liver damage, the applicant conducted the following tests:
test subjects: SD rats, female, 6 weeks old, weight 200 g-220 g/animal, 56 total, purchased from Silikedada test animals, Inc., Hunan province, license number: SCXK (Xiang) 2019-.
The rats were fed adaptively for 3 days and were randomly divided into 7 groups, a normal control group, a model control group, a positive control group, an arabinoxylan low dose group, an arabinoxylan high dose group, an arabinoxylan complex group i, and an arabinoxylan complex group ii. The positive control group is gavaged with 40mg/kg per day, the low-dose group of the arabinoxylan is gavaged with 1g/kg of the arabinoxylan prepared in the embodiment 1 per day, the high-dose group of the arabinoxylan is gavaged with 1.5g/kg of the arabinoxylan prepared in the embodiment 1 per day, the group of the arabinoxylan complex is gavaged with 1g/kg of the arabinoxylan complex per day, the normal control group and the model control group are gavaged with physiological saline, the gastric perfusion capacity is 4 mL/mouse, free drinking water is realized during the test period, and the rat standard is used for maintaining the feeding with the pellet feed.
After 14 days of continuous dosing, all rats were fasted for 24h, during which time water was freely available. The group II is continuously gavaged for 14 days according to the dosage, fasting is carried out for 24 hours, and the group II is gavaged for one time 1 hour before the treatment with alcohol. Except for the normal control group, the other groups were gavaged with absolute ethanol to induce gastric injury, 1.0 mL/mouse. After 1 hour of the gavage with absolute ethanol, blood serum was collected from the carotid artery, and the contents of ALT (alanine transferase) and AST (aspartate transferase) in the blood serum were measured, and the results are shown in table 1. All rats are dislocated and killed after blood collection, the stomach is taken, the rat is cut along the greater curvature of the stomach, PBS is used for cleaning, the gastric mucosa is developed, water is sucked by paper, the damage condition of the gastric mucosa layer is carefully observed, and the representative graph of the damage condition of the gastric mucosa of the rats in each test group is shown in figures 1-2. Meanwhile, the number of bleeding points is recorded, the length and the width of an ulcer strip are measured by using a vernier caliper, histological scoring is carried out on gastric lesions according to a macroscopic evaluation scoring table for calculating the ulcer degree according to the national food and drug administration (CFDA publication No. 107, revised in 2012), the injury incidence and the injury inhibition rate of rats in each group are calculated, the stomach mucosa injury scoring standard is shown in a table 2, and the injury incidence and the injury inhibition rate are shown in a table 3.
After histological scoring, each stomach was cut in half, and half of the stomach was used for tissue homogenization to detect the contents of SOD and MDA in the gastric mucosa tissue (if the homogenization was not immediately detected, the contents could be stored at-80 ℃), and the gastric mucosa damage index was calculated, and the damage index results are shown in table 4. The other half of the stomach, where the gastric mucosa is most severely damaged, is excised and then processed as follows to prepare HE stained sections and observe the pathological changes of the sections (if processing is not done immediately, the excised damaged parts can be fixed in neutral formalin solution):
(1) dehydrating each tissue according to the following steps: 50% ethanol (90min) → 70% ethanol (90min) → 85% ethanol (90min) → 95% ethanol (90min) → 100% ethanol (60 min).
(2) The dehydrated tissue is transparent according to the following steps: 1/2 ethanol +1/2 xylene → xylene for 60min each step.
(3) The transparent tissue was waxed at 62 ℃ according to the following procedure: 1/2 xylene +1/2 paraffin (90min) → paraffin I (120min) → paraffin II (120 min).
(4) Placing the tissue in a mold containing paraffin, placing the mold, pouring molten paraffin, and cooling.
(5) Fixing the embedded tissue wax block in a slicer, cutting into slices with thickness of about 4 μm, spreading in a water bath, taking out the slices on a polylysine film-attached glass slide, numbering, and baking at 65 deg.C for 4 h.
(6) And E, performing HE staining on the section by using an HE staining kit, and observing the pathological change condition of the section. The pathological section of the damage condition of the gastric mucosa of rats in each group is shown in figure 3.
The calculation formulas of the injury incidence, the injury inhibition rate and the injury index are as follows:
(1) incidence of injury (%) = number of bleeding or ulceration rats appearing in a group/number of rats in the group × 100%
(2) Damage inhibition (%) = (A-B)/A × 100% (A is damage integral of model control group, B is damage integral of other test group)
(3) Injury index = sum of group injury scores/number of animals in group
Alanine transferase and aspartate transferase in serum are labeled enzymes reflecting the degree of liver injury, and as is apparent from table 1, the enzyme index of rats in a model control group is seriously increased to indicate that the liver is seriously injured, while the enzyme index of rats given with the arabinoxylan or the compound thereof of the invention tends to be normal, which indicates that the arabinoxylan and the compound thereof of the invention have a protective effect on alcoholic liver injury. As can be seen from Table 3, ethanol can obviously cause bleeding of rat gastric mucosa, which causes gastric mucosa injury, and the arabinoxylan and the compound thereof can effectively inhibit the rat gastric mucosa injury caused by alcohol. As can be seen from Table 4, both the arabinoxylans and the complexes thereof of the invention can significantly reduce the damage index of ethanol to rat gastric mucosa. As can be seen from figures 1-2, the arabinoxylan and the compound thereof can obviously reduce the damage degree of ethanol to rat gastric mucosa. As can be seen from FIG. 3, the degeneration and necrosis of the epithelial cells of the gastric mucosa of the rats in the model control group cause the infiltration of inflammatory cells which account for about 45-60% of the epithelium; the gastric mucosa of the rats in the high-dose arabinoxylan group also has inflammatory cell infiltration, but the damage degree is smaller than that of a model control group, and the damaged part of the rats accounts for about 14-29% of the epithelium; the structure of the gastric mucosa of rats in the first and second groups of the arabinoxylan compound is basically normal, and inflammatory cell infiltration is rarely seen. The pathological results obtained by whole gastric mucosa observation and HE staining slice observation are basically consistent with the general (integral) observation score result, and the arabinoxylan and the compound thereof can be judged to have protective and therapeutic effects on alcoholic gastric mucosa injury.
According to the stipulation in the evaluation method (manuscript in request) for auxiliary protection function of gastric mucosa injury provided by food and drug administration: the invention relates to a method for preparing a compound of arabinoxylan and a compound of arabinoxylan, which is characterized in that the arabinoxylan and the compound of arabinoxylan can reduce the incidence rate of the gastric mucosa injury of rats, can obviously reduce the gastric mucosa injury index of rats and improve the gastric mucosa injury inhibition rate of rats, and can also be supported pathologically, so that the arabinoxylan and the compound of arabinoxylan can be judged to have the effects of prevention, auxiliary protection and treatment on the gastric mucosa.
The present invention is not limited to the above preferred embodiments, and various other forms of the product can be obtained by anyone with the benefit of the present disclosure, but any variation on the details thereof, which is the same as or similar to the technical solution of the present invention, falls within the protection scope of the present invention.
Claims (10)
1. Application of arabinoxylan or its compound with rhizoma Amorphophalli powder in preparing food, health product or medicine for preventing/treating alcoholic gastrointestinal mucosa and liver injury is provided.
2. The use according to claim 1, wherein the mass ratio of the arabinoxylan to the konjac flour in the arabinoxylan-konjac flour composite is 1-99%.
3. Use according to claim 1 or 2, wherein the arabinoxylan has a glycan content > 60%.
4. Use according to claim 1 or 2, wherein the glucomannan content of the konjac flour is > 60%.
5. The use of claim 1 or 2, wherein the arabinoxylan is prepared from plant raw materials by pretreatment, impurity removal, alkali extraction, and dealkalization purification.
6. The use according to claim 5, wherein the plant material comprises one or more of straw, corncob, bran or wood having a hemicellulose component comprising arabinoxylan as a main component.
7. The use according to claim 5, wherein the arabinoxylan is prepared by the following specific method:
(1) crushing plant raw materials, adding 8-12 times of NaOH solution with the weight and the mass concentration of 0.2-1.0%, carrying out heat preservation treatment at 40-90 ℃ for 1.5-2.5 h, replacing and washing with clear water, and then filtering and dehydrating to obtain clean fibers;
(2) adding 6-10 times of NaOH solution with the weight and the mass concentration of 8-12% into the obtained clean fiber, performing heat preservation extraction at 55-65 ℃ for 5.5-6.5 h, settling, centrifuging and collecting primary supernatant, performing continuous countercurrent displacement on the residue by using 8-12 times of NaOH solution with the mass concentration of 3-5%, settling and centrifuging the displacement solution, collecting secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain an arabinoxylan alkali solution;
(3) and (3) dealkalizing the arabinoxylan alkali solution, adding acid to neutralize the solution until the pH value is 6.0-8.0, concentrating and dehydrating the solution, adding clear water to perform continuous replacement desalting treatment, and drying the solution to obtain the arabinoxylan alkali solution.
8. The use of claim 7, wherein the dealkalization in step (3) can be performed by one or a combination of ultrafiltration membrane filtration and electrodialysis membrane replacement.
9. The use according to claim 1, wherein the arabinoxylan alone or the complex of the arabinoxylan and the konjac flour is optionally added with conventional adjuvants, and made into granules, powders, tablets, capsules or suspensions according to conventional processes, and used as common food, health food or medicine.
10. The use according to claim 1 or 9, wherein the arabinoxylan alone or the complex of the arabinoxylan with the konjac flour is added to any other processed food or food material, functioning through different food carriers; the different food carriers comprise rice, flour products, dairy products, vegetable protein products and dry and fresh fruit juice products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110135233.2A CN112691115A (en) | 2021-02-01 | 2021-02-01 | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110135233.2A CN112691115A (en) | 2021-02-01 | 2021-02-01 | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112691115A true CN112691115A (en) | 2021-04-23 |
Family
ID=75516454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110135233.2A Pending CN112691115A (en) | 2021-02-01 | 2021-02-01 | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112691115A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113796538A (en) * | 2021-08-06 | 2021-12-17 | 上海赛普瑞特生物科技有限公司 | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence |
| CN113875871A (en) * | 2021-10-11 | 2022-01-04 | 唐传生物科技（厦门）有限公司 | Health sugar |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004065156A (en) * | 2002-08-08 | 2004-03-04 | Genmai Koso:Kk | Method for producing composition for inhibiting onset of liver cancer, and composition |
| CN101531722A (en) * | 2009-04-16 | 2009-09-16 | 江苏康维生物有限公司 | Improved method for preparing plant xylan through extraction by alkali method |
| CN102065847A (en) * | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | Pharmaceutical formulation containing angiotensin-II receptor blocker |
| CN104431361A (en) * | 2014-12-03 | 2015-03-25 | 中国人民解放军总后勤部军需装备研究所 | Application of wheat AX (arabinoxylan) extracts to improving intestinal tract barrier function |
| CN105696396A (en) * | 2016-03-24 | 2016-06-22 | 广西壮族自治区中国科学院广西植物研究所 | Method for recovering hemicellulose, lignin and alkaline liquor from hemicellulose extraction liquid by separating flow |
| CN108359026A (en) * | 2018-05-11 | 2018-08-03 | 桂林纤元生物技术有限公司 | A kind of preparation method and its usage of water-insoluble xylan |
-
2021
- 2021-02-01 CN CN202110135233.2A patent/CN112691115A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004065156A (en) * | 2002-08-08 | 2004-03-04 | Genmai Koso:Kk | Method for producing composition for inhibiting onset of liver cancer, and composition |
| CN102065847A (en) * | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | Pharmaceutical formulation containing angiotensin-II receptor blocker |
| CN101531722A (en) * | 2009-04-16 | 2009-09-16 | 江苏康维生物有限公司 | Improved method for preparing plant xylan through extraction by alkali method |
| CN104431361A (en) * | 2014-12-03 | 2015-03-25 | 中国人民解放军总后勤部军需装备研究所 | Application of wheat AX (arabinoxylan) extracts to improving intestinal tract barrier function |
| CN105696396A (en) * | 2016-03-24 | 2016-06-22 | 广西壮族自治区中国科学院广西植物研究所 | Method for recovering hemicellulose, lignin and alkaline liquor from hemicellulose extraction liquid by separating flow |
| CN108359026A (en) * | 2018-05-11 | 2018-08-03 | 桂林纤元生物技术有限公司 | A kind of preparation method and its usage of water-insoluble xylan |
Non-Patent Citations (4)
| Title |
|---|
| CAROLINE MELLINGER-SILVA，等: "Isolation of a gastroprotective arabinoxylan from sugarcane bagasse", 《BIORESOURCE TECHNOLOGY》 * |
| 付元芳，等: "阿拉伯木聚糖对高脂日粮诱导大鼠脂质代谢和肝脏损伤的影响", 《2017年四川省食品与营养学术年会论文集》 * |
| 沈玖君，等: "魔芋粉对小鼠急性酒精性胃黏膜损伤和慢性酒精性肠损伤的影响", 《食品科学》 * |
| 黄利华，等: "根茎淀粉植物皮渣中膳食纤维的研究进展", 《广州城市职业学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113796538A (en) * | 2021-08-06 | 2021-12-17 | 上海赛普瑞特生物科技有限公司 | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence |
| CN113875871A (en) * | 2021-10-11 | 2022-01-04 | 唐传生物科技（厦门）有限公司 | Health sugar |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dou et al. | Digestive property and bioactivity of blackberry polysaccharides with different molecular weights | |
| Nie et al. | Bioactive polysaccharides from Cordyceps sinensis: Isolation, structure features and bioactivities | |
| JP4044599B2 (en) | Kawaratake strain and its extract and use thereof | |
| JP5249817B2 (en) | Immunostimulated fermented food from fructan-containing food | |
| JP2004519220A (en) | Method for producing pectin hydrolyzate | |
| TW200904340A (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
| CN112691115A (en) | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury | |
| CN111040044B (en) | Cordyceps militaris intracellular polysaccharide, preparation method and application thereof in regulating intestinal flora | |
| CN106213523A (en) | A kind of extracting method of Salicornia Bigelovii Torr. dietary fiber | |
| CN113480676B (en) | Oligogalacturonic acid polysaccharide, compound, preparation method and application thereof | |
| KR20140138490A (en) | Fermented Sparassis crispa and method for preparing the same | |
| CN110772630A (en) | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof | |
| Zhou et al. | Fabrication of quercetin-loaded nanoparticles based on Hohenbuehelia serotina polysaccharides and their modulatory effects on intestinal function and gut microbiota in vivo | |
| Lu et al. | Effects of exopolysaccharides from Antrodia cinnamomea on inflammation and intestinal microbiota disturbance induced by antibiotics in mice | |
| CN113730444A (en) | Application of soluble dietary fiber in kelp in preparation of medicines and functional foods for improving ulcerative colitis | |
| JPH03285653A (en) | Fat metabolism improving substance and production thereof | |
| JP2012085591A (en) | Diet food product | |
| JPWO2009078495A1 (en) | Insoluble dietary fiber-containing substances derived from cereal plant seeds | |
| CN114989258B (en) | Application of plant extract composition in preparing product for treating constipation and reducing weight | |
| CN114304640B (en) | Polysaccharide composition for protecting gastric mucosa and preparation method and application thereof | |
| KR20140128135A (en) | Anti-cholesterol and anti-obesity use of alginic acid oligosaccharide | |
| JPH06247861A (en) | Antiulcer agent and its production | |
| WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
| KR20110132887A (en) | Composition for improving hepatic, stomachic function and curing hangover | |
| JP3191956B2 (en) | Alcoholic fatty liver inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |